Posted by Michael Wonder on 03 Feb 2025
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer
3 February 2025 - Recommendation based on ADRIATIC Phase 3 trial results which showed a 27% reduction in the risk of death versus placebo
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.
